Entering text into the input field will update the search result below

FDA OKs expanded use for Amgen's Nplate

Oct. 18, 2019 9:20 AM ETAmgen Inc. (AMGN) StockAMGNBy: Douglas W. House, SA News Editor
  • The FDA approves Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for use in newly diagnosed adults with immune thrombocytopenia (ITP) (low blood platelets) who have not responded adequately to corticosteroids, immunoglobulins or splenectomy (spleen removal).
  • The agency approved the thrombopoietin receptor agonist in August 2008 for the long-term treatment of adults with chronic ITP and in December 2018 for pediatric ITP patients.

Recommended For You

More Trending News

About AMGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.